News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
30 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17605)
Month
January (3339)
February (3294)
March (4068)
April (3458)
May (4782)
June (3455)
July (2690)
August (3589)
September (3334)
October (3977)
November (4082)
December (2500)
Day
1 (294)
2 (128)
3 (30)
4 (20)
5 (264)
6 (194)
7 (150)
8 (159)
9 (95)
10 (10)
11 (8)
12 (137)
13 (166)
14 (123)
15 (170)
16 (72)
17 (10)
18 (2)
19 (50)
20 (198)
21 (150)
22 (154)
23 (90)
24 (16)
25 (13)
26 (171)
27 (177)
28 (163)
29 (150)
30 (91)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan
Affimed N.V. announced the presentation at the American Society of Clinical Oncology Annual Meeting of safety and efficacy data from the EGFR mutant NSCLC expansion cohort of its ongoing phase 1/2 study investigating innate cell engager AFM24 as monotherapy.
June 3, 2023
·
10 min read
Drug Development
Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers
Precigen, Inc. presented positive clinical data from the Phase 1 study of the off-the-shelf PRGN-2009 AdenoVerse™ immunotherapy alone and in combination with an investigational anti-PDL1/TGF-Beta Trap checkpoint inhibitor in patients with recurrent/metastatic HPV-associated cancers at the 2023 American Society of Clinical Oncology Annual Meeting.
June 3, 2023
·
11 min read
Genetown
Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Replimune Group, Inc. announced updated data from the first 75 patients in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial along with data from the ongoing Phase 1 trial of RP2 combined with nivolumab in patients with uveal melanoma are being presented at the ASCO annual meeting.
June 3, 2023
·
11 min read
Drug Development
Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1
Sutro Biopharma, Inc. announced that results from a Phase 1 dose-expansion study of luveltamab tazevibulin, a novel Folate receptor alpha -targeting ADC, in patients with advanced ovarian cancer were featured in an oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting in Chicago, IL.
June 3, 2023
·
7 min read
Drug Development
Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma
The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the pivotal Phase 1/2 MonumenTAL-1 study of the investigational bispecific antibody talquetamab in the treatment of patients with relapsed or refractory multiple myeloma.
June 3, 2023
·
25 min read
Drug Development
LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial
LYNPARZA ® (olaparib) and IMFINZI ® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial WILMINGTON, Del.--( BUSINESS WIRE )-- Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA ® (olaparib), IMFINZI ® (durvalumab), chemotherapy and bevac
June 3, 2023
·
45 min read
Genetown
Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting
Blueprint Medicines Corporation announced clinical data for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology Annual Meeting.
June 3, 2023
·
11 min read
Drug Development
NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
NewAmsterdam Pharma Company N.V. announced the full results of ROSE2, a Phase 2 clinical trial evaluating obicetrapib, the Company’s oral, low-dose and once-daily cholesteryl ester transfer protein inhibitor, in combination with ezetimibe as an adjunct to high-intensity statin therapy.
June 3, 2023
·
14 min read
Bio NC
GRAIL Presents Real-World Experience With The Galleri® Multi-Cancer Early Detection Test At 2023 ASCO Annual Meeting
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced data evaluating the Galleri® multi-cancer early detection test’s ability to detect a cancer signal and predict the cancer signal origin in asymptomatic individuals in the real-world setting.
June 3, 2023
·
8 min read
Drug Development
Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting
Innovent Biologics, Inc. updated the Phase 1b efficacy and safety results of IBI939 combined with sintilimab in previously untreated PD-L1-selected NSCLC without sensitizing mutations at the 2023 American Society of Clinical Oncology Annual Meeting.
June 3, 2023
·
7 min read
Previous
3 of 3